project id: TCGA-PRAD; case submitter id: TCGA-YJ-A8SW; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.86; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.74; rna integrity number: 9.5; age at index: 67; ethnicity: not reported; gender: male; race: not reported; vital status: Alive; year of birth: 1941; ajcc clinical t: T1c; ajcc pathologic n: N0; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 148.0; icd 10 code: C61.9; last known disease status: not reported; morphology: 8480/3; primary diagnosis: Mucinous adenocarcinoma; primary gleason grade: Pattern 5; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2008; treatment or therapy: not reported; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 2051; initial weight: 1000.0; sample id: 8a96a7a8-0413-42b9-9173-fd63761dd83a; sample submitter id: TCGA-YJ-A8SW-01A; portion id: fb283431-e98b-411f-96b3-372da310498d; portion submitter id: TCGA-YJ-A8SW-01A-11; slide id: b5fdc456-41fd-4a6b-86af-342c253bf2ee; slide submitter id: TCGA-YJ-A8SW-01A-01-TSA; percent lymphocyte infiltration: 5.0; percent monocyte infiltration: 0.0; percent necrosis: 5.0; percent neutrophil infiltration: 0.0; percent normal cells: 5.0; percent stromal cells: 25.0; percent tumor cells: 65.0; percent tumor nuclei: 70.0; section location: TOP;